This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloproliferative neoplasms.
David Snyder, MD
Advertisement
Articles by David Snyder, MD
Advertisement
Latest Updated Articles
- Outlook for 2017: Myeloma, Lymphoma, and MPNs
Published: December 24th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
HR 2541: How May Its Implementation Impact Radiation Oncology Practice?
2
Handling the Burden of Financial Toxicity While Undergoing Cancer Therapy
3
HRQOL Finds Similar Responses Between Surgery/Treatment Options in NMIBC
4
How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?
5
